Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients
- PMID: 25852010
- DOI: 10.1007/s00259-015-3046-1
Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients
Abstract
Purpose: (11)C-methionine (MET) PET is an established diagnostic tool for glioma. Studies have suggested that MET uptake intensity in the tumor is a useful index for predicting patient outcome. Because MET uptake is known to reflect tumor expansion more accurately than MRI, we aimed to elucidate the association between volume-based tumor measurements and patient prognosis.
Methods: The study population comprised 52 patients with newly diagnosed glioma who underwent PET scanning 20 min after injection of 370 MBq MET. The tumor was contoured using a threshold of 1.3 times the activity of the contralateral normal cortex. Metabolic tumor volume (MTV) was defined as the total volume within the boundary. Total lesion methionine uptake (TLMU) was defined as MTV times the mean standardized uptake value (SUVmean) within the boundary. The tumor-to-normal ratio (TNR), calculated as the maximum standardized uptake value (SUVmax) divided by the contralateral reference value, was also recorded. All patients underwent surgery (biopsy or tumor resection) targeting the tissue with high MET uptake. The Kaplan-Meier method was used to estimate the predictive value of each measurement.
Results: Grade II tumor was diagnosed in 12 patients (3 diffuse astrocytoma, 2 oligodendroglioma, and 7 oligoastrocytoma), grade III in 18 patients (8 anaplastic astrocytoma, 6 anaplastic oligodendroglioma, and 4 anaplastic oligoastrocytoma), and grade IV in 22 patients (all glioblastoma). TNR, MTV and TLMU were 3.1 ± 1.2, 51.6 ± 49.9 ml and 147.7 ± 153.3 ml, respectively. None of the three measurements was able to categorize the glioma patients in terms of survival when all patients were analyzed. However, when only patients with astrocytic tumor (N = 33) were analyzed (i.e., when those with oligodendroglial components were excluded), MTV and TLMU successfully predicted patient outcome with higher values associated with a poorer prognosis (P < 0.05 and P < 0.01, respectively), while the predictive ability of TNR did not reach statistical significance (P = NS).
Conclusion: MTV and TLMU may be useful for predicting outcome in patients with astrocytic tumor.
Similar articles
-
Association Between Pretreatment 11C-Methionine Positron Emission Tomography Metrics, Histology, and Prognosis in 125 Newly Diagnosed Patients with Adult-Type Diffuse Glioma Based on the World Health Organization 2021Classification.World Neurosurg. 2024 Jun;186:e495-e505. doi: 10.1016/j.wneu.2024.03.164. Epub 2024 Apr 5. World Neurosurg. 2024. PMID: 38583563
-
Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.Ann Nucl Med. 2016 Feb;30(2):89-96. doi: 10.1007/s12149-015-1035-x. Epub 2015 Oct 28. Ann Nucl Med. 2016. PMID: 26511019
-
Prognostic value of post-treatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma.Neurosurg Rev. 2017 Apr;40(2):223-229. doi: 10.1007/s10143-016-0748-1. Epub 2016 Jun 10. Neurosurg Rev. 2017. PMID: 27282449
-
Imaging gliomas with positron emission tomography and single-photon emission computed tomography.Semin Nucl Med. 2003 Apr;33(2):148-62. doi: 10.1053/snuc.2003.127304. Semin Nucl Med. 2003. PMID: 12756647 Review.
-
Prognostic Value of the Metabolic and Volumetric Parameters of 11C-Methionine Positron-Emission Tomography for Gliomas: A Systematic Review and Meta-Analysis.AJNR Am J Neuroradiol. 2018 Sep;39(9):1629-1634. doi: 10.3174/ajnr.A5707. Epub 2018 Jun 28. AJNR Am J Neuroradiol. 2018. PMID: 29954817 Free PMC article.
Cited by
-
Differentiating high-grade glioma progression from treatment-related changes with dynamic [18F]FDOPA PET: a multicentric study.Eur Radiol. 2023 Apr;33(4):2548-2560. doi: 10.1007/s00330-022-09221-4. Epub 2022 Nov 11. Eur Radiol. 2023. PMID: 36367578
-
11C-methionine PET imaging characteristics in children with diffuse intrinsic pontine gliomas and relationship to survival and H3 K27M mutation status.Eur J Nucl Med Mol Imaging. 2023 May;50(6):1709-1719. doi: 10.1007/s00259-022-06105-z. Epub 2023 Jan 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 36697961
-
Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma.Nucl Med Mol Imaging. 2015 Dec;49(4):291-7. doi: 10.1007/s13139-015-0362-0. Epub 2015 Aug 29. Nucl Med Mol Imaging. 2015. PMID: 26550048 Free PMC article.
-
MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis.Neurosurg Rev. 2019 Jun;42(2):185-195. doi: 10.1007/s10143-017-0906-0. Epub 2017 Sep 16. Neurosurg Rev. 2019. PMID: 28918564 Free PMC article.
-
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.Clin Nucl Med. 2017 May;42(5):341-347. doi: 10.1097/RLU.0000000000001577. Clin Nucl Med. 2017. PMID: 28195901 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous